{"id":18959,"date":"2021-12-02T09:43:33","date_gmt":"2021-12-02T08:43:33","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=18959"},"modified":"2021-12-02T09:43:37","modified_gmt":"2021-12-02T08:43:37","slug":"2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/bilans-rapports-et-recommandations\/2021-antimicrobial-resistance-benchmark-report-by-the-access-to-medicine-atm-foundation\/","title":{"rendered":"2021 antimicrobial resistance benchmark report, by the Access to Medicine (AtM) Foundation"},"content":{"rendered":"\n

Article published on 18 November 2021 on the Access to medicine foundation<\/a> website<\/p>\n\n\n\n

The Access to Medicine (AtM) Foundation has released its 2021 antimicrobial resistance benchmark report evaluating 17 of the industry\u2019s most active players in the AMR space.\u00a0<\/p>\n\n\n\n

GSK maintained its lead among multinational corporations, although Pfizer leaped from sixth to a close second place after making \u201csignificant strides\u201d in stewardship, waste management, drug access, R&D and data sharing. <\/p>\n\n\n\n

The AtM Foundation praised Pfizer as the only major multinational making its raw data public. In the generics manufacturer group, Aurobindo, Abbott and Viatris made the list as new leaders in first, second and third place, respectively.\u00a0<\/p>\n\n\n\n

According to the press release, \u201cgood practice is becoming more common,\u201d but industry is showing a \u201clack of momentum.\u201d Companies missed opportunities to improve access to LMICs with the highest need and \u201cremain focused on a small set of countries, people, and diseases,\u201d the report said.<\/p>\n\n\n\n